frontiers in Genome Editing

CORRECTION
published: 17 May 2021
doi: 10.3389/fgeed.2021.682171

Edited and reviewed by:
Pietro Genovese, Boston Children's Hospital and Harvard Medical School, United States

***Correspondence:**
Mario Amendola
mamendola@genethon.fr

†Present address:
Giulia Pavani, The Children's Hospital of Philadelphia, Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Philadelphia, PA, United States

Specialty section:
This article was submitted to Genome Editing in Blood Disorders, a section of the journal Frontiers in Genome Editing

Received: 17 March 2021
Accepted: 06 April 2021
Published: 17 May 2021

Citation:
Pavani G and Amendola M (2021) Corrigendum: Targeted Gene Delivery: Where to Land. Front. Genome Ed. 3:682171. doi: 10.3389/fgeed.2021.682171

Corrigendum: Targeted Gene Delivery: Where to Land

*Giulia Pavani† and Mario Amendola**

INTEGRARE, UMR_S951, Genethon, Inserm, Univ Evry, Univ Paris-Saclay, Evry, France

Keywords: genome editing, gene therapy, nuclease, CRISPR, targeted integration (TI), knock-in, safe harbor, homologous recombination (HR)

A Corrigendum on

Targeted Gene Delivery: Where to Land
by Pavani, G., and Amendola, M. (2021). Front. Genome Ed. 2:609650. doi: 10.3389/fgeed.2020.609650

In the original article, there was a mistake in **Table 1** as published. The references indicated in row **B** are wrong. The corrected **Table 1** appears in the attached below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

TABLE 1 | (A–F) The advantages and disadvantages of different integration strategies.

	Integration strategies		Advantages	Disadvantages	References
A	Endogenous locus		Physiological transgene expression Corrects multiple mutations	Gene-specific strategy Limited to gene body mutations	Urnov et al., 2005; Lombardo et al., 2007; Li et al., 2011; Genovese et al., 2014; Voit et al., 2014; Dever et al., 2016; Hubbard et al., 2016; Schiroli et al., 2017; Sweeney et al., 2017; Kuo et al., 2018; Wang et al., 2019; Rai et al., 2020; Wang L. et al., 2020
B	Superactive promoters (ALB, HBA)		Accommodates different transgenes Supraphysiological expression Few integrations required	Partial gene disruption Limited to non-cell autonomous disorders Extensive validation required	Barzel et al., 2015; Sharma et al., 2015; Davidoff and Nathwani, 2016; Laoharawee et al., 2018; Chen et al., 2019; Conway et al., 2019; De Caneva et al., 2019; Ou et al., 2019, 2020; Zhang et al., 2019; Wang Q. et al., 2020
C	Tolerant to integration (AAVS1, CCR5, Rosa26)		Accommodates different transgenes	Artificial promoters required Variable expression	De Ravin et al., 2016; Diez et al., 2017; Stephens et al., 2018, 2019; Gomez-Ospina et al., 2019; Scharenberg et al., 2020
D	Chromatin domains (NAD)		Fine gene regulation Far from oncogenic genes	No proof-of-principle in clinically relevant models	Schenkwein et al., 2020
E	Disease-modifier genes (CCR5, HBA)		Improve therapeutic effect Lower therapeutic threshold	Extensive validation required Limited to well-known diseases	Voit et al., 2013; Wiebking et al., 2018
F	Specificity Exchange (TCR, BCR)		Improved CAR expression and potency	Off-targets Translocations risk (for multiple edits)	Eyquem et al., 2017; MacLeod et al., 2017; Greiner et al., 2019; Hartweger et al., 2019; Moffett et al., 2019; Voss et al., 2019

Scissors: nuclease; Solid arrows: promoters; Enh, enhancers; TAD, topologically associating; d, domain; Solid ovals: histone modifications; Solid squares: DNA modifications.

REFERENCES

Barzel, A., Paulk, N. K., Shi, Y., Huang, Y., Chu, K., Zhang, F., et al. (2015). Promoterless gene targeting without nucleases ameliorates haemophilia B in mice. *Nature* 517, 360–364. doi: 10.1038/nature13864

Chen, H., Shi, M., Gilam, A., Zheng, Q., Zhang, Y., Afrikanova, I., et al. (2019). Hemophilia A ameliorated in mice by CRISPR-based *in vivo* genome editing of human factor. *Sci. Rep.* 9:16838. doi: 10.1038/s41598-019-53198-y

Conway, A., Mendel, M., Kim, K., McGovern, K., Boyko, A., Zhang, L., et al. (2019). Non-viral delivery of zinc finger nuclease mRNA enables highly efficient *in vivo* genome editing of multiple therapeutic gene targets. *Mol. Ther.* 27, 866–877. doi: 10.1016/j.ymthe.2019.03.003

Davidoff, A. M., and Nathwani, A. C. (2016). Genetic targeting of the albumin locus to treat Hemophilia. *N. Engl. J. Med.* 374, 1288–1290. doi: 10.1056/NEJMcibr1600347

De Caneva, A., Porro, F., Bortolussi, G., Sola, R., Lisjak, M., Barzel, A., et al. (2019). Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases. *JCI Insight*. 5:128863. doi: 10.1172/jci.insight.128863

De Ravin, S. S., Reik, A., Liu, P. Q., Li, L., Wu, X., Su, L., et al. (2016). Targeted gene addition in human CD34(+) hematopoietic cells for correction of X-linked chronic granulomatous disease. *Nat. Biotechnol.* 34, 424–429. doi: 10.1038/nbt.3513

Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., et al. (2016). CRISPR/Cas9 beta-globin gene targeting in human haematopoietic stem cells. *Nature* 539, 384–389. doi: 10.1038/nature20134

Diez, B., Genovese, P., Roman-Rodriguez, F. J., Alvarez, L., Schiroli, G., Ugalde, L., et al. (2017). Therapeutic gene editing in CD34(+) hematopoietic progenitors from Fanconi anemia patients. *EMBO Mol. Med.* 9, 1574–1588. doi: 10.15252/emmm.201707540

Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J., Hamieh, M., Cunanan, K. M., et al. (2017). Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. *Nature* 543, 113–117. doi: 10.1038/nature21405

Genovese, P., Schiroli, G., Escobar, G., Tomaso, T. D., Firrito, C., Calabria, A., et al. (2014). Targeted genome editing in human repopulating haematopoietic stem cells. *Nature* 510, 235–240. doi: 10.1038/nature13420

Gomez-Ospina, N., Scharenberg, S. G., Mostrel, N., Bak, R. O., Mantri, S., Quadros, R. M., et al. (2019). Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type. *Nat. Commun.* 10:4045. doi: 10.1038/s41467-019-11962-8

Greiner, V., Bou Puerto, R., Liu, S., Herbel, C., Carmona, E. M., and Goldberg, M. S. (2019). CRISPR-mediated editing of the B cell receptor in primary human B cells. *iScience* 12, 369–378. doi: 10.1016/j.isci.2019.01.032

Hartweger, H., McGuire, A. T., Horning, M., Taylor, J. J., Dosenovic, P., Yost, D., et al. (2019). HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells. *J. Exp. Med.* 216, 1301–1310. doi: 10.1084/jem.20190287

Hubbard, N., Hagin, D., Sommer, K., Song, Y., Khan, I., Clough, C., et al. (2016). Targeted gene editing restores regulated CD40L function in X-linked hyper-IgM syndrome. *Blood* 127, 2513–2522. doi: 10.1182/blood-2015-11-683235

Kuo, C. Y., Long, J. D., Campo-Fernandez, B., de Oliveira, S., Cooper, A. R., Romero, Z., et al. (2018). Site-specific gene editing of human hematopoietic stem cells for X-linked hyper-IgM syndrome. *Cell Rep.* 23, 2606–2616. doi: 10.1016/j.celrep.2018.04.103

Laoharawee, K., DeKelver, R. C., Podetz-Pedersen, K. M., Rohde, M., Sproul, S., Nguyen, H. O., et al. (2018). Dose-dependent prevention of metabolic and neurologic disease in murine MPS II by ZFN-mediated *in vivo* genome editing. *Mol. Ther.* 26, 1127–1136. doi: 10.1016/j.ymthe.2018.03.002

Li, H., Haurigot, V., Doyon, Y., Li, T., Wong, S. Y., Bhagwat, A. S., et al. (2011). *In vivo* genome editing restores haemostasis in a mouse model of haemophilia. *Nature* 475, 217–221. doi: 10.1038/nature10177

Lombardo, A., Genovese, P., Beausejour, C. M., Colleoni, S., Lee, Y. L., Kim, K. A., et al. (2007). Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. *Nat. Biotechnol.* 25, 1298–1306. doi: 10.1038/nbt1353

MacLeod, D. T., Antony, J., Martin, A. J., Moser, R. J., Hekele, A., Wetzel, K. J., et al. (2017). Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cells. *Mol. Ther.* 25, 949–961. doi: 10.1016/j.ymthe.2017.02.005

Moffett, H. F., Harms, C. K., Fitzpatrick, K. S., Tooley, M. R., Boonyaratanakornkit, J., and Taylor, J. J. (2019). B cells engineered to express pathogen-specific antibodies protect against infection. *Sci. Immunol.* 4:aax0644. doi: 10.1126/sciimmunol.aax0644

Ou, L., DeKelver, R. C., Rohde, M., Tom, S., Radeke, R., St Martin, S. J., et al. (2019). ZFN-mediated *in vivo* genome editing corrects murine hurler syndrome. *Mol. Ther.* 27, 178–187. doi: 10.1016/j.ymthe.2018.10.018

Ou, L., Przybilla, M. J., Ahlat, O., Kim, S., Overn, P., Jarnes, J., et al. (2020). A highly efficacious PS gene editing system corrects metabolic and neurological complications of Mucopolysaccharidosis type I. *Mol. Ther.* 28, 1442–1454. doi: 10.1016/j.ymthe.2020.03.018

Rai, R., Romito, M., Rivers, E., Turchiano, G., Blattner, G., Vetharoy, W., et al. (2020). Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott - Aldrich Syndrome. *Nat. Commun.* 11:4034. doi: 10.1038/s41467-020-17626-2

Scharenberg, S. G., Poletto, E., Lucot, K. L., Colella, P., Sheikali, A., Montine, T. J., et al. (2020). Engineering monocyte/macrophage-specific glucocerebrosidase expression in human hematopoietic stem cells using genome editing. *Nat. Commun.* 11:3327. doi: 10.1038/s41467-020-17148-x

Schenkwein, D., Afzal, S., Nousiainen, A., Schmidt, M., and Yla-Herttuala, S. (2020). Efficient nuclease-directed integration of lentivirus vectors into the human ribosomal DNA locus. *Mol. Ther.* 28, 1858–1875. doi: 10.1016/j.ymthe.2020.05.019

Schiroli, G., Ferrari, S., Conway, A., Jacob, A., Capo, V., Albano, L., et al. (2017). Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1. *Sci. Transl. Med.* 9:aan0820. doi: 10.1126/scitranslmed.aan0820

Sharma, R., Anguela, X. M., Doyon, Y., Wechsler, T., DeKelver, R. C., Sproul, S., et al. (2015). *In vivo* genome editing of the albumin locus as a platform for protein replacement therapy. *Blood* 126, 1777–1784. doi: 10.1182/blood-2014-12-615492

Stephens, C. J., Kashentseva, E., Everett, W., Kaliberova, L., and Curiel, D. T. (2018). Targeted *in vivo* knock-in of human alpha-1-antitrypsin cDNA using adenoviral delivery of CRISPR/Cas9. *Gene Ther.* 25, 139–156. doi: 10.1038/s41434-018-0003-1

Stephens, C. J., Lauron, E. J., Kashentseva, E., Lu, Z. H., Yokoyama, W. M., and Curiel, D. T. (2019). Long-term correction of hemophilia B using adenoviral delivery of CRISPR/Cas9. *J. Contr. Release.* 298, 128–141. doi: 10.1016/j.jconrel.2019.02.009

Sweeney, C. L., Zou, J., Choi, U., Merling, R. K., Liu, A., Bodansky, A., et al. (2017). Targeted repair of CYBB in X-CGD iPSCs requires retention of intronic sequences for expression and functional correction. *Mol. Ther.* 25, 321–330. doi: 10.1016/j.ymthe.2016.11.012

Urnov, F. D., Miller, J. C., Lee, Y. L., Beausejour, C. M., Rock, J. M., Augustus, S., et al. (2005). Highly efficient endogenous human gene correction using designed zinc-finger nucleases. *Nature* 435, 646–651. doi: 10.1038/nature03556

Voit, R. A., Hendel, A., Pruett-Miller, S. M., and Porteus, M. H. (2014). Nuclease-mediated gene editing by homologous recombination of the human globin locus. *Nucl. Acids Res.* 42, 1365–1378. doi: 10.1093/nar/gkt947

Voit, R. A., McMahon, M. A., Sawyer, S. L., and Porteus, M. H. (2013). Generation of an HIV resistant T-cell line by targeted "stacking" of restriction factors. *Mol. Ther.* 21, 786–795. doi: 10.1038/mt.2012.284

Voss, J. E., Gonzalez-Martin, A., Andrabi, R., Fuller, R. P., Murrell, B., McCoy, L. E., et al. (2019). Reprogramming the antigen specificity of B cells using genome-editing technologies. *Elife* 8:42995. doi: 10.7554/eLife.42995

Wang, L., Yang, Y., Breton, C., Bell, P., Li, M., Zhang, J., et al. (2020). A mutation-independent CRISPR-Cas9-mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency. *Sci. Adv.* 6:eaax5701. doi: 10.1126/sciadv.aax5701

Wang, L., Yang, Y., Breton, C. A., White, J., Zhang, J., Che, Y., et al. (2019). CRISPR/Cas9-mediated *in vivo* gene targeting corrects hemostasis in newborn and adult factor IX-knockout mice. *Blood* 133, 2745–2752. doi: 10.1182/blood.2019000790

Wang, Q., Zhong, X., Li, Q., Su, J., Liu, Y., Mo, L., et al. (2020). CRISPR-Cas9-mediated *in vivo* gene integration at the albumin locus recovers hemostasis in neonatal and adult hemophilia B mice. *Mol. Ther. Methods Clin. Dev.* 18, 520–531. doi: 10.1016/j.omtm.2020.06.025

Wiebking, V., Patterson, J. O., Martin, R., Chanda, M. K., Lee, C. M., Srifa, W., et al. (2018). Metabolic engineering generates a transgene-free safety switch for cell therapy. *Nat. Biotechnol* 2020:6. doi: 10.1038/s41587-020-0580-6

Zhang, J. P., Cheng, X. X., Zhao, M., Li, G. H., Xu, J., Zhang, F., et al. (2019). Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse. *Genome Biol.* 20:276. doi: 10.1186/s13059-019-1907-9